Key facts
- Notable investors include Sichuan Development Fund, Chengdu Bio-Town Investment, Huaxi Securities Investment, Shangshan Goldstone Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Peide Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Peide Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Peide Biomedical
Developer of innovative peptide drugs based on an animal venom peptide directional mining system. The company has a natural active peptide library independently developed and constructed, and conducts peptide drug screening and development through the high-throughput and cloud computing screening platform and AI artificial intelligence platform, and develops innovative peptide drugs, enabling clients to improve treatment efficiency.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2021
- Website
- pdbio.com.cn/
- Ownership
- Privately Held (backing)
Peide Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peide Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peide Biomedical in its N-PORT filings yet. We sweep new filings monthly.